Outside of vaccines, GlaxoSmithKline isn’t a major producer of biologics compared with some of its Big Pharma peers. But it has just signed a big deal to scale up ma...

Amid widespread speculation on COVID-19 vaccine timelines, former Biomedical Advanced Research and Development Authority (BARDA) chief turned whistleblower...

WuXi Biologics has angled for years to expand its manufacturing base out of China and into promising hubs in Europe and the U.S. Now, nearly two years after its plan...

AstraZeneca, partnered with the University of Oxford on a leading COVID-19 vaccine candidate, has already inked a deal to supply millions of doses&nbs...

As questions swirl over equitable access to COVID-19 vaccines, Sanofi CEO Paul Hudson has laid out some of his company’s plans should its program succeed, Bloomberg ...

Back in January, Merck said Keytruda—its anti-PD-1 therapy—had missed the mark in an area where two of its rivals had succeeded. Both those rivals are anti-PD-L...

When Bristol Myers Squibb said last October that its combination of Opdivo, Yervoy and chemo had topped solo chemo at lengthening patients’ lives, analysts and inves...

Just days away from an FDA decision that could finally bring Bristol Myers Squibb’s Opdivo to previously untreated non-small cell lung cancer patients, the company’s...

Right now, Roche’s Tecentriq is the only drug in its class with an approval in previously untreated, metastatic triple-negative breast cancer, a particularly aggress...

Rebiotix and Ferring Pharmaceuticals have unveiled positive preliminary findings from an ongoing pivotal late-stage trial of the investigational microbiome-based tre...